Adaptive Biotechnologies ImmunoSeq T-Map COVID Service
Aug 04, 2020
Adaptive Biotechnologies has launched the immunoSeq T-Map COVID, a proprietary research product and data-analysis service to measure the T cell immune response to vaccines in development and track the persistence of that response over time.
The product leverages data from more than 1,000 patients to provide researchers with a quantitative map of T cell receptors and SARS-CoV-2 antigens that elicit an immune response. These data will be available through Adaptive's cloud-based immunoSeq Analyzer and is powered by ImmuneCode, an open database developed in partnership with Microsoft.